Items tagged with Access
Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships (post with simple image)
The initiative will allow countries to access delamanid through the Stop TB Partnership’s Global Drug Facility at a price of US$ 1700 for each full-course treatment of six months’ duration.
UNITAID study looks at delinking cost of R&D from price of medicines (post with simple image)
The study explores how to separate the costs of research and development (R&D) from the future market price of vaccines, medicines and diagnostics – a concept known as “delinkage”.
UAEM calls for a people-centered approach to biomedical R&D (post with simple image)
Universities Allied for Essential Medicines (UAEM) launches Re:Route, a mapping of alternative biomedical research and development (R&D) initiatives.
Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments (post with simple image)
Médecins Sans Frontières released the 4th edition of its report DR-TB Drugs Under the Microscope. The report analyzes the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis.
WHO: Developing countries need smart IP systems for local medicines production (post with simple image)
The World Health Organization has released a report on the role of intellectual property in local production of medicines in developing countries. According to the report, the way countries design their intellectual property system is key in the development of local innovation and production. However, health outcomes will depend on the accessibility and affordability of good-quality essential medicines.
Lives on the Edge: Time to align medical research and development with people’s health needs (post with simple image)
Médecins Sans Frontières (MSF) released a report that outlines shortcomings of the current system for new drug development. The report highlights resulting access barriers and proposes policy solutions.
Stop TB Partnership Global Drug Facility announces 70 percent price reduction for linezolid (post with simple image)
Linezolid is a critical component of regimens used to treat multidrug-resistant tuberculosis (MDR-TB). The GDF-negotiated price reduction is projected to save up to US$ 30 million over the next three years, helping to further improve equitable access to MDR-TB treatment.
Stop TB Partnership launches seven key population briefs (post with simple image)
The Stop TB Partnership released a series of briefs on TB key populations recognizing that reaching everyone with services, diagnostics, treatment and care is essential to ending the TB epidemic. The briefs focus on children, miners, mobile populations, urban populations, prisoners, rural populations and people who use drugs.
Global Fund and Stop TB Partnership sign Memorandum of Understanding with Global Drug Facility (post with simple image)
The Stop TB Partnership signed a Memorandum of Understanding with the Global Fund to Fight AIDS, Tuberculosis and Malaria to optimize access to TB health products and pharmaceutical services in countries receiving Global Fund financing for TB.
Call to Action to accelerate access to DR-TB drugs: 2016 update (post with simple image)
The update informs about the general progress in the introduction of bedaquiline and delamanid in TB programs worldwide and reports on the requests made in the Call to Action issued in March 2015.
Page 45 of 51 · Total posts: 0←First 44 45 46 Last→